VF
REVB icon

Virtu Financial’s Revelation Biosciences REVB Stock Holding History

Virtu Financial’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12
Closed -$63K – 1786
2023
Q2 		$63K Buy
+12
New +$75.2K ﹤0.01% 1108
2022
Q2 		– Hold
0
– -$17K – 1986
2022
Q1 		– Hold
0
– – – 1317

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Virtu Financial's REVB Position: Q3 2023 in Review

Virtu Financial sold out of Revelation Biosciences (REVB) in Q3 2023, closing a stake of 12 shares — an estimated $63K sold.

Virtu Financial first reported a position in REVB in Q2 2023 and held it in 1 quarter. The position peaked at $63K in Q2 2023. 6 funds tracked by Wall St. Rank hold REVB as of Q3 2023.

  • Virtu Financial reported no remaining Revelation Biosciences position as of Q3 2023 after selling out during the quarter.
  • Virtu Financial sold 12 Revelation Biosciences shares in Q3 2023, an estimated $63K.
  • Virtu Financial first reported a position in Revelation Biosciences in Q2 2023 and held it in 1 quarter.
  • Virtu Financial's Revelation Biosciences position peaked at $63K in Q2 2023.
  • 6 funds tracked by Wall St. Rank held Revelation Biosciences as of Q3 2023.

Based on Virtu Financial's 13F filing for Q3 2023, filed 15 Nov 2023.